Vericel price target lowered to $35 from $53 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Vericel to $35 from $53 and keeps a Buy rating on the shares post the Q3 results. The analyst cites softer near-term MACI growth for the target drop.